Black Swift Group LLC Trims Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Black Swift Group LLC cut its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 87.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,000 shares of the company's stock after selling 33,500 shares during the quarter. Black Swift Group LLC's holdings in TransMedics Group were worth $312,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Principal Financial Group Inc. grew its holdings in TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after buying an additional 146,115 shares in the last quarter. State of Michigan Retirement System purchased a new position in TransMedics Group during the fourth quarter valued at approximately $6,734,000. Public Sector Pension Investment Board purchased a new position in TransMedics Group during the third quarter valued at approximately $11,079,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in TransMedics Group by 665.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company's stock worth $11,716,000 after acquiring an additional 64,872 shares during the period. Finally, Vaughan Nelson Investment Management L.P. lifted its stake in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company's stock worth $51,654,000 after purchasing an additional 64,360 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Remove Ads

TransMedics Group Trading Down 2.1 %

Shares of TMDX traded down $1.43 during mid-day trading on Monday, hitting $66.03. 949,904 shares of the company's stock traded hands, compared to its average volume of 2,038,117. The business's 50-day moving average price is $68.30 and its 200-day moving average price is $97.19. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm has a market capitalization of $2.22 billion, a P/E ratio of 70.25 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on TMDX shares. Robert W. Baird decreased their price target on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a report on Wednesday, December 11th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, February 5th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Canaccord Genuity Group cut their price objective on TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a report on Wednesday, November 20th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and an average price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.